Cargando…

Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis

Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. A number of treatment agents have undergone assessment in humans following promising results in animal models. Currently, about 50 therapeutic agents are in various stages o...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Paul N, Dillon, John F, McCrimmon, Rory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835815/
https://www.ncbi.nlm.nih.gov/pubmed/36694893
http://dx.doi.org/10.17925/EE.2022.18.2.148
_version_ 1784868744988721152
author Brennan, Paul N
Dillon, John F
McCrimmon, Rory
author_facet Brennan, Paul N
Dillon, John F
McCrimmon, Rory
author_sort Brennan, Paul N
collection PubMed
description Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. A number of treatment agents have undergone assessment in humans following promising results in animal models. Currently, about 50 therapeutic agents are in various stages of development. Recently, however, there have been a number of exciting and positive developments in this landscape, although there are inherent challenges ahead. In this article, we review the aetiological and pathological basis of NASH progression and describe putative targets for current therapies. We also discuss some of the likely future directions and difficulties around this complex and challenging disease paradigm.
format Online
Article
Text
id pubmed-9835815
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Touch Medical Media
record_format MEDLINE/PubMed
spelling pubmed-98358152023-01-23 Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis Brennan, Paul N Dillon, John F McCrimmon, Rory touchREV Endocrinol Liver Disorders Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. A number of treatment agents have undergone assessment in humans following promising results in animal models. Currently, about 50 therapeutic agents are in various stages of development. Recently, however, there have been a number of exciting and positive developments in this landscape, although there are inherent challenges ahead. In this article, we review the aetiological and pathological basis of NASH progression and describe putative targets for current therapies. We also discuss some of the likely future directions and difficulties around this complex and challenging disease paradigm. Touch Medical Media 2022-11 2022-11-22 /pmc/articles/PMC9835815/ /pubmed/36694893 http://dx.doi.org/10.17925/EE.2022.18.2.148 Text en © Touch Medical Media 2022 ali:free_to_read www.copyright.com (http://www.copyright.com) Disclosures: John F Dillon has received research grants and lecture honoraria from MSD, Abbvie and Gilead. Paul N Brennan and Rory McCrimmon have no financial or non-financial relationships or activities to declare in relation to this article. Review process: Double-blind peer review. Compliance with ethics: This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors. Data availability: Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article. Authorship: The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. https://creativecommons.org/licenses/by/3.0/Access: This article is freely accessible at touchENDOCRINOLOGY.com (http://touchENDOCRINOLOGY.com) © Touch Medical Media 2022
spellingShingle Liver Disorders
Brennan, Paul N
Dillon, John F
McCrimmon, Rory
Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
title Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
title_full Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
title_fullStr Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
title_full_unstemmed Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
title_short Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
title_sort advances and emerging therapies in the treatment of non-alcoholic steatohepatitis
topic Liver Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835815/
https://www.ncbi.nlm.nih.gov/pubmed/36694893
http://dx.doi.org/10.17925/EE.2022.18.2.148
work_keys_str_mv AT brennanpauln advancesandemergingtherapiesinthetreatmentofnonalcoholicsteatohepatitis
AT dillonjohnf advancesandemergingtherapiesinthetreatmentofnonalcoholicsteatohepatitis
AT mccrimmonrory advancesandemergingtherapiesinthetreatmentofnonalcoholicsteatohepatitis